Drug Law Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Law Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Alzheimer Disease
Research in the area of Alzheimer disease reported from Helsinki University
June 26th, 2007
Researchers detail in "Effects of NMDA receptor antagonist memantine on mismatch negativity," new data in Alzheimer disease. "Mismatch negativity (MMN) and its magnetic counterpart (MMNm) have been shown to be altered in patients with various psychiatric and neurological disorders, e.g. Alzheimer's disease and schizophrenia, indicating deficits in involuntary attention," scientists writing in the journal Brain Research Bulletin report. "N-Methyl-D-aspartate (NMDA) receptor-mediated glutamate dysfunction is suggested to underlie these deficits. However, the role of NMDA receptors in involuntary attention is poorly understood. Memantine is an NMDA receptor...
Source: Drug Law Weekly (2007-06-26)
|
